Richmond, Jan. 16, 2024 (GLOBE NEWSWIRE) -- According to a research report "Targeted Protein Degradation Market”, By Technology {PROTACs (Proteolysis-Targeting Chimeras), LYTACs (Lysosome-Targeting Chimeras), SNIPERs (Specific and Non-genetic IAP-dependent Protein ERasers), Molecular glues}, By Therapeutic Area (Neurological Disorders, Oncological Disorders, Others), By Route of administration (Oral, Intravenous and Others) and Region - Global Forecast to 2030.
Global Targeted Protein Degradation Market Report Scope:
| Report | Details |
| Market size value in 2023 | USD 113.8 Billion |
| Market size value in 2030 | USD 247.5 Billion |
| CAGR (2023-2030) | 10.2% |
| Forecast Period | 2023–2030 |
| Historic Data | 2019 |
| Forecast Units | Value (USD Million/USD Billion) |
| Segments Covered | Technology, Therapeutic Area, Route of administration and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and RoW |
| |
| |
| Sample of Companies Covered |
|
| |
|
Download the Sample - https://www.marketdigits.com/request/sample/3825
TOC Covers in Depth & Breath on Targeted Protein Degradation Market
170 - Market Data Tables
65 - List of Figures
225 – Pages
The report includes Vendor Assessment (Company Profiles, Market Positioning, Strategies, Recent Developments, Capabilities & Product Offerings / Mapping), Technology Assessment (Developments & Economic Impact), Partner & Customer Ecosystem (Product Services, Proposition & Key Features) Competitive Index & Regional FootPrint by MarketDigits.
Market Overview
The targeted protein degradation market has been gaining significant attention within the pharmaceutical and biotechnology sectors. This innovative approach offers a novel therapeutic strategy by selectively eliminating disease-causing proteins within the cell. The demand for targeted protein degradation technologies has been rising due to the potential they hold in addressing diseases that were traditionally challenging to treat. Key players in the market have been actively involved in research and development to advance their drug candidates through clinical trials. Proteolysis-targeting chimeras (PROTACs) and other protein degradation technologies have shown promise in preclinical studies, targeting specific proteins implicated in various diseases, including cancer and neurodegenerative disorders. Investments and collaborations within the industry have been contributing to the expansion of the market. Pharmaceutical companies are increasingly recognizing the potential of targeted protein degradation in expanding their therapeutic pipelines. Regulatory approvals and successful clinical outcomes of key drug candidates will likely have a substantial impact on the market's growth.
Major Vendors in the Global Targeted Protein Degradation Market:
- Arvinas, Inc.
- Bayer AG
- C4 Therapeutics, Inc.
- Cellestia Biotech AG
- Cullgen Inc.
- Cyrus Biotechnology, Inc.
- Daiichi Sankyo Co., Ltd.
- Kymera Therapeutics, Inc.
- Mirati Therapeutics, Inc.
- Nurix Therapeutics, Inc.
- Peptidream Inc.
- Progenra Inc.
- Proteolix, Inc.
- Sanofi S.A.
- Shield Therapeutics, Inc.
- Syros Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Vivace Therapeutics, Inc.
- Xencor, Inc.
- Zenith Epigenetics Ltd.
Request for Discount @ https://www.marketdigits.com/request/discount/3825
Increasing recognition of the therapeutic potential of targeted protein degradation in addressing previously undruggable targets
One key driver fueling the growth of the Global Targeted Protein Degradation Market is the increasing recognition of the therapeutic potential of targeted protein degradation in addressing previously undruggable targets. Traditional drug discovery has faced challenges in developing treatments for diseases associated with specific proteins that were considered difficult to modulate. Targeted protein degradation technologies, such as PROTACs, offer a unique approach by inducing the degradation of disease-causing proteins within cells, providing a novel avenue for treating conditions like cancer and neurodegenerative disorders. As pharmaceutical and biotechnology companies witness the success of preclinical studies and early-phase clinical trials, there is a growing enthusiasm for incorporating targeted protein degradation strategies into drug development pipelines. This enthusiasm is translating into heightened research and investment, driving the market forward as stakeholders recognize the potential of these innovative approaches to revolutionize therapeutic interventions.
Market Dynamics
Drivers:
- High demand for effective treatments
- Targeting previously undruggable proteins
- Increased research and development
Opportunities:
- Expanding range of therapeutic applications
- Development of oral TPD drugs
Potential expansion of therapeutic applications beyond oncology
A significant opportunity in the Global Targeted Protein Degradation Market lies in the potential expansion of therapeutic applications beyond oncology. While the initial focus of targeted protein degradation technologies has been on addressing cancer-related targets, there is a growing realization of their versatility in treating a broader range of diseases. Researchers and companies are exploring the applicability of these technologies in various therapeutic areas, including autoimmune disorders, neurodegenerative diseases, and genetic disorders. As the understanding of protein degradation mechanisms deepens, there is an opportunity to develop novel therapies for diseases with limited treatment options. The ability of targeted protein degradation to modulate a diverse array of proteins implicated in different conditions positions it as a versatile platform for drug development. This expanding landscape of potential applications presents a key opportunity for market players to diversify their portfolios and address unmet medical needs across various therapeutic domains, thereby fostering sustained growth in the Global Targeted Protein Degradation Market.
The Market for Targeted Protein Degradation is Dominated by North America.
In 2022, North America presently leads the targeted protein degradation market, boasting the highest market share. This dominance is ascribed to the abundance of pharmaceutical and biotechnology companies in the region, coupled with significant investments in research and development initiatives. Nevertheless, the Asia Pacific region is poised to experience the most substantial growth rate in the targeted protein degradation market. This surge is a result of escalating investments in healthcare infrastructure and research and development, particularly in countries like China, Japan, and India. Furthermore, the region's large population, coupled with significant unmet medical needs, is fostering a heightened demand for innovative therapies, including targeted protein degradation.
The Infant Formula Segments is anticipated to hold the Largest Market Share during the Forecast Period
In terms of technology, the global market is segmented into several categories, including PROTACs (Proteolysis-Targeting Chimeras), LYTACs (Lysosome-Targeting Chimeras), SNIPERs (Specific and Non-genetic IAP-dependent Protein ERasers), Molecular glues, and others. Currently, PROTACs dominate the targeted protein degradation market in terms of technology. PROTACs, or Proteolysis-Targeting Chimeras, are small molecules that can enlist target proteins to E3 ubiquitin ligases. These ligases catalyze the ubiquitination process, leading to the subsequent degradation of the target protein by the proteasome. The attention garnered by PROTACs in recent years is substantial, primarily owing to their capability to selectively target disease-causing proteins, even those previously deemed "undruggable" using conventional methods. Consequently, numerous pharmaceutical companies are making significant investments in PROTAC research and development, thereby propelling the market's growth.
Inquire Before Buying: https://www.marketdigits.com/request/enquiry-before-buying/3825
Browse Similar Reports:
Protein Engineering Market 2030 By Type, Distribution Channel, End-user and Region - Partner & Customer Ecosystem (Product Services, Proposition & Key Features) Competitive Index & Regional Footprints by MarketDigits
Protein Labeling Market 2023 – 2030 by Application (Cell-Based Assay, Fluorescence Microscopy, Immunological Technique), Product (Reagents, Kits, & Services), Labeling Method (In Vitro Labeling, In Vivo Labeling), Partner & Customer Ecosystem (Product Services, Proposition & Key Features) Competitive Index & Regional Footprints by MarketDigits
Mammalian Transient Protein Expression Market 2030 By Type, Distribution Channel, End-user and Region - Partner & Customer Ecosystem (Product Services, Proposition & Key Features) Competitive Index & Regional Footprints by MarketDigits
About MarketDigits:
MarketDigits is one of the leading business research and consulting companies that helps clients to tap new and emerging opportunities and revenue areas, thereby assisting them in operational and strategic decision-making. We at MarketDigits believe that a market is a small place and an interface between the supplier and the consumer, thus our focus remains mainly on business research that includes the entire value chain and not only the markets.
We offer services that are most relevant and beneficial to the users, which help businesses to sustain themselves in this competitive market. Our detailed and in-depth analysis of the markets catering to strategic, tactical, and operational data analysis & reporting needs of various industries utilize advanced technology so that our clients get better insights into the markets and identify lucrative opportunities and areas of incremental revenues.
Contact Us:
MarketDigits
1248 CarMia Way Richmond,
VA 23235,
United States.
USA: +1 847 450 0808
Email: sales@marketdigits.com
Web: https://www.marketdigits.com
Follow Us on: | Twitter | LinkedIn |
